Search results
1 lip 2019 · The current study examines the efficacy, safety, and tolerability of ASP8273 versus erlotinib or gefitinib in patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations not previously treated with an EGFR inhibitor.
14 gru 2017 · ASP8273 demonstrated antitumor activity in patients with EGFR-mutant lung cancers after prior treatment with EGFR TKIs. This study identified the ASP8273 RP2D to be 300 mg daily based on pharmacokinetics, pharmacodynamics, safety, and antitumor activity; the MTD was not established.
ASP8273 was administered orally once daily (QD) and all patients were assessed for AEs, PK and preliminary anti-tumor activity. Dose-escalation and MTD estimation were conducted based on Bayesian-CRM.
9 sie 2018 · Based on preclinical activity, ASP8273 was evaluated in a phase I/II study in patients with EGFR‐mutant lung cancer in Japan. The primary objectives for phase I of this study were to assess safety/tolerability of ASP8273 as well as to determine the MTD and/or the RP2D based on the DLT profile.
15 gru 2017 · ASP8273 is a third-generation EGFR TKI with antitumor activity in preclinical models of EGFR-mutant lung cancer that targets mutant EGFR, including EGFR T790M. Experimental Design: In this multicohort, phase I study ( NCT02113813 ), escalating doses of ASP8273 (25-500 mg) were administered once daily to non-small cell lung cancer (NSCLC ...
1 lip 2019 · The current study examines the efficacy, safety, and tolerability of ASP8273 versus erlotinib or gefitinib in patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations not previously treated with an EGFR inhibitor.
20 maj 2016 · Described here are the preliminary antitumor effects of the RP2D in EGFR mutation-positive non-small cell lung cancer (NSCLC) previously treated with an EGFR TKI (most patients received ≥ 1 prior treatment) in 2 study populations: all subjects and subjects with T790M.
